Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBIT Margin (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed EBIT Margin for 9 consecutive years, with 7382.41% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin fell 667875.0% year-over-year to 7382.41%; the TTM value through Mar 2026 reached 381.67%, up 58389.0%, while the annual FY2025 figure was 340.38%, 25458.0% up from the prior year.
  • EBIT Margin hit 7382.41% in Q1 2026 for Bicycle Therapeutics, down from 51.52% in the prior quarter.
  • Across five years, EBIT Margin topped out at 51.52% in Q4 2025 and bottomed at 7382.41% in Q1 2026.
  • Average EBIT Margin over 5 years is 1310.08%, with a median of 709.4% recorded in 2022.
  • Year-over-year, EBIT Margin surged 182723bps in 2025 and then crashed -667875bps in 2026.
  • Bicycle Therapeutics' EBIT Margin stood at 383.46% in 2022, then tumbled by -165bps to 1017.35% in 2023, then tumbled by -79bps to 1824.78% in 2024, then skyrocketed by 97bps to 51.52% in 2025, then crashed by -14228bps to 7382.41% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 7382.41%, 51.52%, and 558.64% for Q1 2026, Q4 2025, and Q3 2025 respectively.